{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T11:55:24Z","timestamp":1794225324031,"version":"4.8.0"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100001819","name":"International Rett Syndrome Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020265","name":"Stan Perron Charitable Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>The clinical, research and advocacy communities for Rett syndrome are striving to achieve clinical trial readiness, including having fit-for-purpose clinical outcome assessments. This study aimed to (1) describe psychometric properties of clinical outcome assessment for Rett syndrome and (2) identify what is needed to ensure that fit-for-purpose clinical outcome assessments are available for clinical trials.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Clinical outcome assessments for the top 10 priority domains identified in the Voice of the Patient Report for Rett syndrome were compiled and available psychometric data were extracted. The clinical outcome assessments measured clinical severity, functional abilities, comorbidities and quality of life, and electrophysiological biomarkers. An international and multidisciplinary panel of 29 experts with clinical, research, psychometric, biostatistical, industry and lived experience was identified through International Rett Syndrome Foundation networks, to discuss validation of the clinical outcome assessments, gaps and next steps, during a workshop and in a follow-up questionnaire. The identified gaps and limitations were coded using inductive content analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Variable validation profiles across 26 clinical outcome assessments of clinical severity, functional abilities, and comorbidities were discussed. Reliability, validity, and responsiveness profiles were mostly incomplete; there were limited content validation data, particularly parent-informed relevance, comprehensiveness and comprehensibility of items; and no data on meaningful change or cross-cultural validity. The panel identified needs for standardised administration protocols and systematic validation programmes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>A pipeline of collaborative clinical outcome assessment development and validation research in Rett syndrome can now be designed, aiming to have fit-for-purpose measures that can evaluate meaningful change, to serve future clinical trials and clinical practice.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-024-08678-6","type":"journal-article","created":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T13:42:41Z","timestamp":1734788561000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["International workshop: what is needed to ensure outcome measures for Rett syndrome are fit-for-purpose for clinical trials? June 7, 2023, Nashville, USA"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7358-9037","authenticated-orcid":false,"given":"Jenny","family":"Downs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6492-622X","authenticated-orcid":false,"given":"Dominique C.","family":"Pichard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8561-8453","authenticated-orcid":false,"given":"Walter E.","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9336-5820","authenticated-orcid":false,"given":"Joseph P.","family":"Horrigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3791-3367","authenticated-orcid":false,"given":"Melissa","family":"Raspa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5448-9046","authenticated-orcid":false,"given":"Gillian","family":"Townend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3264-0902","authenticated-orcid":false,"given":"Eric D.","family":"Marsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6405-5834","authenticated-orcid":false,"given":"Helen","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5713-8399","authenticated-orcid":false,"given":"Kathleen","family":"Motil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2810-2466","authenticated-orcid":false,"given":"Andrew C.","family":"Dietz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1911-4256","authenticated-orcid":false,"given":"Nupur","family":"Garg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9671-2883","authenticated-orcid":false,"given":"Amitha","family":"Ananth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7645-1479","authenticated-orcid":false,"given":"Breanne","family":"Byiers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7439-5402","authenticated-orcid":false,"given":"Sarika","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8352-6694","authenticated-orcid":false,"given":"Christopher","family":"Beatty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9833-4807","authenticated-orcid":false,"given":"Frank","family":"Symons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5551-8956","authenticated-orcid":false,"given":"James","family":"Youakim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0127-7322","authenticated-orcid":false,"given":"Bernhard","family":"Suter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4830-5893","authenticated-orcid":false,"given":"Paramola","family":"Santosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5628-5872","authenticated-orcid":false,"given":"Jeffrey L.","family":"Neul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6969-5061","authenticated-orcid":false,"given":"Tim A.","family":"Benke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,21]]},"reference":[{"key":"8678_CR1","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/13810","volume":"23","author":"RE Amir","year":"1999","unstructured":"Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet. 1999;23:185\u20138.","journal-title":"Nat Genet"},{"key":"8678_CR2","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1203\/PDR.0b013e3182242461","volume":"70","author":"S Fehr","year":"2011","unstructured":"Fehr S, Bebbington A, Nassar N, Downs J, Ronen GM, de Klerk N, Leonard H. Trends in the diagnosis of Rett syndrome in Australia. Pediatr Res. 2011;70:313\u20139.","journal-title":"Pediatr Res"},{"key":"8678_CR3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/ajmg.b.32707","volume":"180","author":"JL Neul","year":"2019","unstructured":"Neul JL, Benke TA, Marsh ED, Skinner SA, Merritt J, Lieberman DN, Standridge S, Feyma T, Heydemann P, Peters S, Ryther R, Jones M, Suter B, Kaufmann WE, Glaze DG, Percy AK. The array of clinical phenotypes of males with mutations in Methyl-CpG binding protein 2. Am J Med Genet B Neuropsychiatr Genet. 2019;180:55\u201367.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"8678_CR4","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.neuroscience.2020.04.037","volume":"445","author":"M Fagiolini","year":"2020","unstructured":"Fagiolini M, Patrizi A, LeBlanc J, Jin LW, Maezawa I, Sinnett S, Gray SJ, Molholm S, Foxe JJ, Johnston MV, Naidu S, Blue M, Hossain A, Kadam S, Zhao X, Chang Q, Zhou Z, Zoghbi H. intellectual and developmental disabilities research centers: a multidisciplinary approach to understand the pathogenesis of Methyl-CpG binding protein 2-related disorders. Neuroscience. 2020;445:190\u2013206.","journal-title":"Neuroscience"},{"key":"8678_CR5","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1002\/ana.22124","volume":"68","author":"J Neul","year":"2010","unstructured":"Neul J, Kaufmann W, Glaze D, Christodoulou J, Clarke A, Bahi-Buisson N, Leonard H, Bailey M, Schanen N, Zappella M, Renieri A, Huppke P, Percy AK. Rett syndrome: revised diagnostic criteria and nomenclature. Ann Neurol. 2010;68:944\u201350.","journal-title":"Ann Neurol"},{"key":"8678_CR6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nrneurol.2016.186","volume":"13","author":"H Leonard","year":"2017","unstructured":"Leonard H, Cobb S, Downs J. Clinical and biological progress over 50 years in Rett syndrome. Nat Rev Neurol. 2017;13:37\u201351.","journal-title":"Nat Rev Neurol"},{"key":"8678_CR7","doi-asserted-by":"publisher","first-page":"e000731","DOI":"10.1136\/bmjpo-2020-000731","volume":"4","author":"C Fu","year":"2020","unstructured":"Fu C, Armstrong D, Marsh E, Lieberman D, Motil K, Witt R, Standridge S, Lane J, Dinkel T, Jones M, Hale K, Suter B, Glaze D, Neul J, Percy A, Benke T. Multisystem comorbidities in classic Rett syndrome: a scoping review. BMJ Paediatr Open. 2020;4:e000731.","journal-title":"BMJ Paediatr Open"},{"key":"8678_CR8","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1212\/01.wnl.0000304752.50773.ec","volume":"70","author":"A Bebbington","year":"2008","unstructured":"Bebbington A, Anderson A, Ravine D, Fyfe S, Pineda M, de Klerk N, Ben-Zeev B, Yatawara N, Percy A, Kaufmann WE, Leonard H. Investigating genotype-phenotype relationships in Rett syndrome using an international data set. Neurology. 2008;70:868\u201375.","journal-title":"Neurology"},{"key":"8678_CR9","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1136\/jmedgenet-2013-102113","volume":"51","author":"V Cuddapah","year":"2014","unstructured":"Cuddapah V, Pillai R, Shekar K, Lane J, Motil K, Skinner S, Tarquinio D, Glaze D, McGwin G, Kaufmann W, Percy A, Neul J, Olsen M. Methyl-CpG-binding protein 2 (MECP2) mutation type is associated with disease severity in Rett syndrome. J Med Genet. 2014;51:152\u20138.","journal-title":"J Med Genet"},{"key":"8678_CR10","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1212\/01.wnl.0000291011.54508.aa","volume":"70","author":"JL Neul","year":"2008","unstructured":"Neul JL, Fang P, Barrish J, Lane J, Caeg EB, Smith EO, Zoghbi H, Percy A, Glaze DG. Specific mutations in methyl-CpG-binding protein 2 confer different severity in Rett syndrome. Neurology. 2008;70:1313\u201321.","journal-title":"Neurology"},{"key":"8678_CR11","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/ajmg.a.34418","volume":"158","author":"NS Halbach","year":"2012","unstructured":"Halbach NS, Smeets EE, van den Braak N, van Roozendaal KE, Blok RM, Schrander-Stumpel CT, Frijns JP, Maaskant MA, Curfs LM. Genotype-phenotype relationships as prognosticators in Rett syndrome should be handled with care in clinical practice. Am J Med Genet A. 2012;158:340\u201350.","journal-title":"Am J Med Genet A"},{"key":"8678_CR12","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/s13023-022-02240-w","volume":"17","author":"H Leonard","year":"2022","unstructured":"Leonard H, Gold W, Samaco R, Sahin M, Benke T, Downs J. Improving clinical trial readiness to accelerate development of new therapeutics for Rett syndrome. Orphanet J Rare Dis. 2022;17:108.","journal-title":"Orphanet J Rare Dis"},{"key":"8678_CR13","unstructured":"Newron Pharmaceuticals. Newron Reports Top-Line Results From Its STARS Study Evaluating Sarizotan in Patients With Rett Syndrome. https:\/\/www.newron.com\/news-and-media\/regulatory-news\/newron-reports-top-line-results-its-stars-study-evaluating-sarizotan .Accessed 15 Apr 2023."},{"key":"8678_CR14","doi-asserted-by":"crossref","unstructured":"Neul JL, Percy AK, Benke TA, Berry-Kravis E, M., Glaze DG, Marsh ED, Lin T, Stankovic S, Bishop KM, Youakim JM. Trofinetide for the treatment of Rett syndrome: a randomized phase 3 study. Nat Med. 2023;29:1468\u201375.","DOI":"10.1038\/s41591-023-02398-1"},{"key":"8678_CR15","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/acn3.533","volume":"5","author":"HM O\u2019Leary","year":"2018","unstructured":"O\u2019Leary HM, Kaufmann WE, Barnes KV, Rakesh K, Kapur K, Tarquinio DC, Cantwell NG, Roche KJ, Rose SA, Walco AC, Bruck NS, Bazin GA, Holm IA, Alexander ME, Swanson LC, Torres JMM, Nelson CA III, Sahin M. Placebo controlled crossover efficacy assessment of Mecasermin for the treatment of Rett syndrome. Ann Clin Transl Neurol. 2018;5:323\u201332.","journal-title":"Ann Clin Transl Neurol"},{"key":"8678_CR16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13023-020-01655-7","volume":"16","author":"Y Naegelin","year":"2021","unstructured":"Naegelin Y, Kuhle J, Sch\u00e4delin S. Fingolimod in children with Rett syndrome: the FINGORETT study. Orphanet J Rare Dis. 2021;16:19.","journal-title":"Orphanet J Rare Dis"},{"key":"8678_CR17","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.pediatrneurol.2023.11.005","volume":"152","author":"JL Neul","year":"2024","unstructured":"Neul JL, Percy AK, Benke TA, Berry-Kravis EM, Glaze DG, Peters SU, Marsh ED, An D, Bishop KM, Youakim JM. Trofinetide treatment demonstrates a benefit over placebo for the ability to communicate in Rett syndrome. Pediatr Neurol. 2024;152:63\u201372.","journal-title":"Pediatr Neurol"},{"key":"8678_CR18","doi-asserted-by":"crossref","unstructured":"Baynam G, Bowman F, Lister K, Walker CE, Pachter N, Goldblatt J, Boycott KM, Gahl WA, Kosaki K, Adachi T, Ishii K, Mahede T, McKenzie F, Townshend S, Slee J, Kiraly-Borri C, Vasudevan A, Hawkins A, Broley S, Schofield L, Verhoef H, Groza T, Zankl A, Robinson PN, Haendel M, Brudno M, Mattick JS, Dinger ME, Roscioli T, Cowley MJ, Olry A, Hanauer M, Alkuraya FS, Taruscio D, Posada de la Paz M, Lochm\u00fcller H, Bushby K, Thompson R, Hedley V, Lasko P, Mina K, Beilby J, Tifft C, Davis M, Laing NG, Julkowska D, Le Cam Y, Terry SF, Kaufmann P, Eerola I, Norstedt I, Rath A, Suematsu M, Groft SC, Austin CP, Draghia-Akli R, Weeramanthri TS, Molster C, Dawkins HJS. Improved diagnosis and care for rare diseases through implementation of precision public health framework. Adv Exp Med Biol. 2017;1031:55\u201394.","DOI":"10.1007\/978-3-319-67144-4_4"},{"key":"8678_CR19","doi-asserted-by":"publisher","unstructured":"Erickson CA, Kaufmann WE, Budimirovic DB, Lachiewicz A, Haas-Givler B, Miller RM, Weber JD, Abbeduto L, Hessl D, Hagerman RJ, Berry-Kravis E. Best practices in fragile X syndrome treatment development. Brain Sci. 2018;8(12):224. https:\/\/doi.org\/10.3390\/brainsci8120224.","DOI":"10.3390\/brainsci8120224"},{"key":"8678_CR20","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/978-3-319-67144-4_5","volume":"1031","author":"R Thompson","year":"2017","unstructured":"Thompson R, Robertson A, Lochm\u00fcller H. Natural history, trial readiness and gene discovery: advances in patient registries for neuromuscular disease. Adv Exp Med Biol. 2017;1031:97\u2013124.","journal-title":"Adv Exp Med Biol"},{"key":"8678_CR21","unstructured":"Coenraads M, Von Hen J, Frank T, Kennedy M, Pichard DC, Palaty C. Voice of the patient report: Rett syndrome externally-led patient-focused drug development meeting. 2022. https:\/\/rettpfdd.org\/site\/assets\/files\/1\/2022-rett-syndrome-voice-of-the-patient-report.pdf. Access 13 Dec 2024."},{"key":"8678_CR22","doi-asserted-by":"crossref","unstructured":"Neul JL, Benke TA, Marsh ED, Suter B, Silveira L, Fu C, Peters SU, Percy AK. Top caregiver concerns in Rett syndrome and related disorders: data from the US natural history study. J Neurodevelopmental disorders 2023;15.","DOI":"10.1186\/s11689-023-09502-z"},{"key":"8678_CR23","unstructured":"Food and Drug Administration. Incorporating Clinical Outcome Assessments into Endpoints for Regulatory Decision-Making.\u00a0US Department of Health and Human Services; 2023. https:\/\/fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-incorporatingclinical-outcome-assessments-endpoints-regulatory. Accessed 13 Dec 2024."},{"key":"8678_CR24","unstructured":"Food and Drug Administration. Patient-Focused Drug Development: Collecting Comprehensive and Representative Input,.\u00a0US Department of Health and Human Services; 2020. https:\/\/fda.gov\/media\/139088\/download. Accessed 13 Dec 2024."},{"key":"8678_CR25","unstructured":"Food and Drug Administration. Patient-focused drug development: Methods to identify what is important to patients.\u00a0US Department of Health and Human Services; 2022. https:\/\/fda.gov\/media\/131230\/download. Accessed 13 Dec 2024."},{"key":"8678_CR26","unstructured":"Food and Drug Adminstration. Patient-Focused Drug Development: Incorporating Clinical Outcome Assessments Into Endpoints for Regulatory Decision-Making, draft guidance. US Department of Health and Human Services; 2023. https:\/\/fda.gov\/regulatory-information\/search-fda-guidance-documents\/patient-focused-drug-development-incorporatingclinical-outcome-assessments-endpoints-regulatory. Accessed 13 Dec 2024."},{"key":"8678_CR27","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1080\/21678707.2016.1229181","volume":"4","author":"WE Kaufmann","year":"2016","unstructured":"Kaufmann WE, Stallworth JL, Everman DB, Skinner SA. Neurobiologically-based treatments for Rett syndrome: opportunities and challenges. Expert Opin Orphan Drugs. 2016;4:1043\u201355.","journal-title":"Expert Opin Orphan Drugs"},{"key":"8678_CR28","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.3390\/diagnostics13101708","volume":"13","author":"M Lotan","year":"2023","unstructured":"Lotan M, Downs J, Stahlhut M, Romano A. Evaluation tools developed for Rett syndrome. Diagnostics. 2023;13:1708.","journal-title":"Diagnostics"},{"key":"8678_CR29","doi-asserted-by":"publisher","first-page":"1229553","DOI":"10.3389\/fped.2023.1229553","volume":"11","author":"AK Percy","year":"2023","unstructured":"Percy AK, Neul JL, Benke TA, Marsh ED, Glaze DG. A review of the Rett Syndrome Behaviour Questionnaire and its utilization in the assessment of symptoms associated with Rett syndrome. Front Pediatr. 2023;11:1229553.","journal-title":"Front Pediatr"},{"key":"8678_CR30","first-page":"13","volume-title":"The Application of Content Analysis in Nursing Science Research","author":"KH Inductive","year":"2020","unstructured":"Inductive KH, Analysis C. In: Kyng\u00e4s H, Mikkonen K, K\u00e4\u00e4ri\u00e4inen M, editors. The Application of Content Analysis in Nursing Science Research. Cham: Springer International Publishing; 2020. p. 13\u201321."},{"key":"8678_CR31","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1007\/s11136-018-1798-3","volume":"27","author":"CAC Prinsen","year":"2018","unstructured":"Prinsen CAC, Mokkink LB, Bouter LM, Alonso J, Patrick DL, de Vet HCW, Terwee CB. COSMIN guideline for systematic reviews of patient-reported outcome measures. Qual Life Res. 2018;27:1147\u201357.","journal-title":"Qual Life Res"},{"key":"8678_CR32","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1007\/s11136-017-1765-4","volume":"27","author":"LB Mokkink","year":"2018","unstructured":"Mokkink LB, de Vet HCW, Prinsen CAC, Patrick DL, Alonso J, Bouter LM, Terwee CB. COSMIN Risk of Bias checklist for systematic reviews of Patient-Reported Outcome Measures. Qual Life Res. 2018;27:1171\u20139.","journal-title":"Qual Life Res"},{"key":"8678_CR33","doi-asserted-by":"publisher","first-page":"5094","DOI":"10.3390\/jcm11175094","volume":"11","author":"J Singh","year":"2022","unstructured":"Singh J, Fiori F, Law ML, Ahmed R, Ameenpur S, Basheer S, Chishti S, Lawrence R, Mastroianni M, Mosaddegh A, Santosh P. Development and Psychometric Properties of the Multi-System Profile of Symptoms Scale in Patients with Rett Syndrome. J Clin Med. 2022;11:5094.","journal-title":"J Clin Med"},{"key":"8678_CR34","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ejpn.2023.07.007","volume":"46","author":"BB Reeve","year":"2023","unstructured":"Reeve BB, Lucas N, Chen D, McFatrich M, Jones HN, Gordon KL, Leiva LZ, Lin L, Coenraads M, von Hehn J, Carpenter RL, Marsh ED, Zigler CK. Validation of the Observer-Reported Communication Ability (ORCA) measure for individuals with Rett syndrome. Eur J Paediatr Neurol. 2023;46:74\u201381.","journal-title":"Eur J Paediatr Neurol"},{"key":"8678_CR35","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1352\/1944-7558-128.3.237","volume":"128","author":"LM Oberman","year":"2023","unstructured":"Oberman LM, Leonard H, Downs J, Cianfaglione R, Stahlhut M, Larsen JL, Madden KV, Kaufmann WE. Rett Syndrome Behaviour Questionnaire in Children and Adults With Rett Syndrome: Psychometric Characterization and Revised Factor Structure. Am J Intellect Dev Disabil. 2023;128:237\u201353.","journal-title":"Am J Intellect Dev Disabil"},{"key":"8678_CR36","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s11136-018-2057-3","volume":"28","author":"J Downs","year":"2019","unstructured":"Downs J, Jacoby P, Leonard H, Epstein A, Murphy N, Davis E, Reddihough D, Whitehouse A, Williams K. Psychometric properties of the Quality of Life Inventory-Disability (QI-Disability) measure. Qual Life Res. 2019;28:783\u201394.","journal-title":"Qual Life Res"},{"key":"8678_CR37","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1007\/s10803-017-3034-3","volume":"47","author":"JB Lane","year":"2017","unstructured":"Lane JB, Salter AR, Jones NE, Cutter G, Horrigan J, Skinner SA, Kaufmann WE, Glaze DG, Neul JL, Percy AK. Assessment of Caregiver Inventory for Rett Syndrome. J Autism Dev Disord. 2017;47:1102\u201312.","journal-title":"J Autism Dev Disord"},{"key":"8678_CR38","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1177\/0883073815579707","volume":"30","author":"JL Neul","year":"2015","unstructured":"Neul JL, Glaze DG, Percy AK, Feyma T, Beisang A, Dinh T, Suter B, Anagnostou E, Snape M, Horrigan J, Jones NE. improving treatment trial outcomes for Rett Syndrome: The development of Rett-specific anchors for the clinical global impression scale. J Child Neurol. 2015;30:1743\u20138.","journal-title":"J Child Neurol"},{"key":"8678_CR39","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.pediatrneurol.2017.07.002","volume":"76","author":"DG Glaze","year":"2017","unstructured":"Glaze DG, Neul JL, Percy A, Feyma T, Beisang A, Yaroshinsky A, Stoms G, Zuchero D, Horrigan J, Glass L, Jones NE. A double-blind, randomized, placebo-controlled clinical study of trofinetide in the treatment of Rett syndrome. Pediatr Neurol. 2017;76:37\u201346.","journal-title":"Pediatr Neurol"},{"key":"8678_CR40","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1352\/1944-7558-125.6.493","volume":"125","author":"M Raspa","year":"2020","unstructured":"Raspa M, Bann CM, Gwaltney A, Benke TA, Fu C, Glaze DG, Haas R, Heydemann P, Jones M, Kaufmann WE, Lieberman D, Marsh E, Peters S, Ryther R, Standridge S, Skinner SA, Percy AK, Neul JL. A Psychometric Evaluation of the Motor-Behavioral Assessment Scale for Use as an Outcome Measure in Rett Syndrome Clinical Trials. Am J Intellect Dev Disabil. 2020;125:493\u2013509.","journal-title":"Am J Intellect Dev Disabil"},{"key":"8678_CR41","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/mds.870050303","volume":"5","author":"PM FitzGerald","year":"1990","unstructured":"FitzGerald PM, Jankovic J, Percy AK. Rett syndrome and associated movement disorders. Mov Disord. 1990;5:195\u2013202.","journal-title":"Mov Disord"},{"key":"8678_CR42","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s13023-022-02259-z","volume":"17","author":"RA Fabio","year":"2022","unstructured":"Fabio RA, Semino M, Giannatiempo S. The GAIRS Checklist: a useful global assessment tool in patients with Rett syndrome. Orphanet J Rare Dis. 2022;17:116.","journal-title":"Orphanet J Rare Dis"},{"key":"8678_CR43","doi-asserted-by":"publisher","first-page":"1388506","DOI":"10.3389\/fneur.2024.1388506","volume":"15","author":"S Leoncini","year":"2024","unstructured":"Leoncini S, Boasiako L, Di Lucia S, Beker A, Scandurra V, Vignoli A, Canevini MP, Prato G, Nobili L, Nicotera AG, Di Rosa G, Chiarini MBT, Cutrera R, Grosso S, Lazzeri G, Tongiorgi E, Morano P, Botteghi M, Barducci A, De Felice C. 24-h continuous non-invasive multiparameter home monitoring of vitals in patients with Rett syndrome by an innovative wearable technology: evidence of an overlooked chronic fatigue status. Front Neurol. 2024;15:1388506.","journal-title":"Front Neurol"},{"key":"8678_CR44","doi-asserted-by":"publisher","unstructured":"Raspa M, Gwaltney A, Bann C, von Hehn J, Benke TA, Marsh ED, Peters SU, Ananth A, Percy AK, Neul JL. Psychometric assessment of the Rett Syndrome Caregiver Assessment of Symptom Severity (RCASS). J Autism Dev Disord. 20245:10.1007\/s10803-024-06238-0. https:\/\/doi.org\/10.1007\/s10803-024-06238-0. Online ahead of print.","DOI":"10.1007\/s10803-024-06238-0"},{"key":"8678_CR45","doi-asserted-by":"publisher","first-page":"106704","DOI":"10.1016\/j.cct.2022.106704","volume":"114","author":"JL Neul","year":"2022","unstructured":"Neul JL, Percy AK, Benke TA, Berry-Kravis EM, Glaze DG, Peters SU, Jones NE, Youakim JM. Design and outcome measures of LAVENDER, a phase 3 study of trofinetide for Rett syndrome. Contemp Clin Trials. 2022;114:106704.","journal-title":"Contemp Clin Trials"},{"key":"8678_CR46","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1111\/j.1469-8749.2010.03636.x","volume":"52","author":"J Downs","year":"2010","unstructured":"Downs J, Bebbington A, Jacoby P, Williams AM, Ghosh S, Kaufmann WE, Leonard H. Level of purposeful hand function as a marker of clinical severity in Rett syndrome. Dev Med Child Neurol. 2010;52:817\u201323.","journal-title":"Dev Med Child Neurol"},{"key":"8678_CR47","doi-asserted-by":"publisher","unstructured":"Downs J, Wong K, Drummond C, Leonard H. Longitudinal evaluation of the stability of hand function in Rett syndrome. J Pediatr. 2021;237:244\u20139.e3. https:\/\/doi.org\/10.1016\/j.jpeds.2021.06.060.","DOI":"10.1016\/j.jpeds.2021.06.060"},{"key":"8678_CR48","doi-asserted-by":"crossref","unstructured":"Leonard H, Benke T, Diener PS, Feltner D, Kaufmann P, Lieberman DN, LoCicero A, Macek TA, McGill BE, Miner JK, Muehring L, Neul JL, O\u2019Keefe JA, Ouyang H, Percy A, Tarquinio DC, Downs J. Establishing clinical trial readiness of the Rett syndrome hand function measure (P1.6\u2013034). Neurology. 2019;92:P1.6\u2013034.","DOI":"10.1212\/WNL.92.15_supplement.P1.6-034"},{"key":"8678_CR49","doi-asserted-by":"publisher","first-page":"e0147555","DOI":"10.1371\/journal.pone.0147555","volume":"11","author":"J Downs","year":"2016","unstructured":"Downs J, Stahlhut M, Wong K, Syhler B, Bisgaard AM, Jacoby P, Leonard H. Validating the Rett syndrome gross motor scale. PLoS ONE. 2016;11:e0147555.","journal-title":"PLoS ONE"},{"key":"8678_CR50","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.pediatrneurol.2019.03.005","volume":"100","author":"ML Rodocanachi Roidi","year":"2019","unstructured":"Rodocanachi Roidi ML, Isaias IU, Cozzi F, Grange F, Scotti FM, Gestra VF, Gandini A, Ripamonti E. A new scale to evaluate motor function in Rett syndrome: validation and psychometric properties. Pediatr Neurol. 2019;100:80\u20136.","journal-title":"Pediatr Neurol"},{"key":"8678_CR51","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1080\/09638288.2016.1212280","volume":"39","author":"M Stahlhut","year":"2017","unstructured":"Stahlhut M, Downs J, Leonard H, Bisgaard AM, Nordmark E. Building the repertoire of measures of walking in Rett syndrome. Disabil Rehabil. 2017;39:1926\u201331.","journal-title":"Disabil Rehabil"},{"key":"8678_CR52","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1080\/09638288.2019.1674389","volume":"43","author":"CS Layne","year":"2021","unstructured":"Layne CS, Young DR, Lee BC, Glaze DG, Schwabe A, Suter B. Kinematics associated with treadmill walking in Rett syndrome. Disabil Rehabil. 2021;43:1585\u201393.","journal-title":"Disabil Rehabil"},{"key":"8678_CR53","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1080\/09638288.2020.1820084","volume":"44","author":"DR Young","year":"2022","unstructured":"Young DR, Suter B, Levine JT, Glaze DG, Layne CS. Characteristic behaviors associated with gait of individuals with Rett syndrome. Disabil Rehabil. 2022;44:1508\u201315.","journal-title":"Disabil Rehabil"},{"key":"8678_CR54","volume-title":"The Vineland Adaptive Behavior Scales","author":"SS Sparrow","year":"1989","unstructured":"Sparrow SS, Cicchetti DV. The Vineland Adaptive Behavior Scales. Boston: Allyn and Bacon; 1989."},{"key":"8678_CR55","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.1365-2788.2011.01404.x","volume":"56","author":"WE Kaufmann","year":"2012","unstructured":"Kaufmann WE, Tierney E, Rohde CA, Suarez-Pedraza MC, Clarke MA, Salorio CF, Bibat G, Bukelis I, Naram D, Lanham DC, Naidu S. Social impairments in Rett syndrome: characteristics and relationship with clinical severity. J Intellect Disabil Res. 2012;56:233\u201347.","journal-title":"J Intellect Disabil Res"},{"key":"8678_CR56","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1212\/WNL.0000000000004515","volume":"89","author":"CL Smith-Hicks","year":"2017","unstructured":"Smith-Hicks CL, Gupta S, Ewen JB, Hong M, Kratz L, Kelley R, Tierney E, Vaurio R, Bibat G, Sanyal A, Yenokyan G, Brereton N, Johnston MV, Naidu S. Randomized open-label trial of dextromethorphan in Rett syndrome. Neurology. 2017;89:1684\u201390.","journal-title":"Neurology"},{"key":"8678_CR57","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1352\/1934-9556-55.6.419","volume":"55","author":"T Clarkson","year":"2017","unstructured":"Clarkson T, LeBlanc J, DeGregorio G, Vogel-Farley V, Barnes K, Kaufmann WE, Nelson CA. Adapting the Mullen scales of early learning for a standardized measure of development in children with Rett syndrome. Intellect Dev Disabil. 2017;55:419\u201331.","journal-title":"Intellect Dev Disabil"},{"key":"8678_CR58","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s10803-004-2544-y","volume":"34","author":"AM Wetherby","year":"2004","unstructured":"Wetherby AM, Woods J, Allen L, Cleary J, Dickinson H, Lord C. Early indicators of autism spectrum disorders in the second year of life. J Autism Dev Disord. 2004;34:473\u201393.","journal-title":"J Autism Dev Disord"},{"key":"8678_CR59","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1352\/1944-7558-128.3.204","volume":"128","author":"CK Zigler","year":"2023","unstructured":"Zigler CK, Lin L, McFatrich M, Lucas N, Gordon KL, Jones HN, Berent A, Panagoulias J, Evans P, Reeve BB. Validation of the Observer-Reported Communication Ability (ORCA) Measure for Individuals With Angelman Syndrome. Am J Intellect Dev Disabil. 2023;128:204\u201318.","journal-title":"Am J Intellect Dev Disabil"},{"key":"8678_CR60","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1097\/MPG.0000000000002951","volume":"72","author":"KJ Motil","year":"2021","unstructured":"Motil KJ, Khan N, Coon JL, Barrish JO, Suter B, Pehlivan D, Schultz RJ, Glaze DG. Gastrointestinal Health Questionnaire for Rett Syndrome: Tool Development. J Pediatr Gatroenterol Nutr. 2021;72:354\u201360.","journal-title":"J Pediatr Gatroenterol Nutr"},{"key":"8678_CR61","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1002\/ajmg.a.37784","volume":"170","author":"S Boban","year":"2016","unstructured":"Boban S, Wong K, Epstein A, Anderson B, Murphy N, Downs J, Leonard H. Determinants of sleep disturbances in Rett syndrome: Novel findings in relation to genotype. Am J Med Genet A. 2016;170:2292\u2013300.","journal-title":"Am J Med Genet A"},{"key":"8678_CR62","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.pediatrneurol.2021.07.009","volume":"123","author":"OJ Veatch","year":"2021","unstructured":"Veatch OJ, Malow BA, Lee HS, Knight A, Barrish JO, Neul JL, Lane JB, Skinner SA, Kaufmann WE, Miller JL, Driscoll DJ, Bird LM, Butler MG, Dykens EM, Gold JA, Kimonis V, Bacino CA, Tan WH, Kothare SV, Peters SU, Percy AK, Glaze DG. Evaluating sleep disturbances in children with rare genetic neurodevelopmental syndromes. Pediatr Neurol. 2021;123:30\u20137.","journal-title":"Pediatr Neurol"},{"key":"8678_CR63","doi-asserted-by":"publisher","first-page":"205520762311916","DOI":"10.1177\/20552076231191622","volume":"9","author":"M Migovich","year":"2023","unstructured":"Migovich M, Ullal A, Fu C, Peters SU, Sarkar N. Feasibility of wearable devices and machine learning for sleep classification in children with Rett syndrome: A pilot study. Digital Health. 2023;9:20552076231191624.","journal-title":"Digital Health"},{"key":"8678_CR64","doi-asserted-by":"publisher","first-page":"4596","DOI":"10.1073\/pnas.1311141111","volume":"111","author":"OS Khwaja","year":"2014","unstructured":"Khwaja OS, Ho E, Barnes KV, O\u2019Leary HM, Pereira LM, Finkelstein Y, Nelson CA 3rd, Vogel-Farley V, DeGregorio G, Holm IA, Khatwa U, Kapur K, Alexander ME, Finnegan DM, Cantwell NG, Walco AC, Rappaport L, Gregas M, Fichorova RN, Shannon MW, Sur M, Kaufmann WE. Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome. Proc Natl Acad Sci U S A. 2014;111:4596\u2013601.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8678_CR65","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s11689-015-9127-4","volume":"7","author":"KV Barnes","year":"2015","unstructured":"Barnes KV, Coughlin FR, O\u2019Leary HM, Bruck N, Bazin GA, Beinecke EB, Walco AC, Cantwell NG, Kaufmann WE. Anxiety-like behavior in Rett syndrome: characteristics and assessment by anxiety scales. J Neurodev Disord. 2015;7:30.","journal-title":"J Neurodev Disord"},{"key":"8678_CR66","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1111\/1469-7610.00236","volume":"43","author":"RH Mount","year":"2002","unstructured":"Mount RH, Charman T, Hastings RP, Reilly S, Cass H. The Rett Syndrome Behaviour Questionnaire (RSBQ): refining the behavioural phenotype of Rett syndrome. J Child Psychol Psychiatry. 2002;43:1099\u2013110.","journal-title":"J Child Psychol Psychiatry"},{"key":"8678_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1352\/0895-8017(2003)108<0001:TABPFR>2.0.CO;2","volume":"108","author":"RH Mount","year":"2003","unstructured":"Mount RH, Hastings RP, Reilly S, Cass H, Charman T. Towards a behavioral phenotype for Rett syndrome. Am J Ment Retard. 2003;108:1\u201312.","journal-title":"Am J Ment Retard"},{"key":"8678_CR68","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s11689-024-09575-4","volume":"16","author":"J Downs","year":"2024","unstructured":"Downs J, Wong K, Leonard H. Associations between genotype, phenotype and behaviours measured by the Rett syndrome behaviour questionnaire in Rett syndrome. J Neurodev Disord. 2024;16:59.","journal-title":"J Neurodev Disord"},{"key":"8678_CR69","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.pediatrneurol.2020.01.009","volume":"107","author":"W Hou","year":"2020","unstructured":"Hou W, Bhattacharya U, Pradana WA, Tarquinio DC. Assessment of a clinical trial metric for rett syndrome: critical analysis of the Rett Syndrome Behavioural Questionnaire. Pediatr Neurol. 2020;107:48\u201356.","journal-title":"Pediatr Neurol"},{"key":"8678_CR70","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1002\/ana.26029","volume":"89","author":"JN Saby","year":"2021","unstructured":"Saby JN, Benke TA, Peters SU, Standridge SM, Matsuzaki J, Cutri-French C, Swanson LC, Lieberman DN, Key AP, Percy AK, Neul JL, Nelson CA, Roberts TPL, Marsh ED. multisite study of evoked potentials in Rett syndrome. Ann Neurol. 2021;89:790\u2013802.","journal-title":"Ann Neurol"},{"key":"8678_CR71","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3389\/fnint.2020.00030","volume":"14","author":"JN Saby","year":"2020","unstructured":"Saby JN, Peters SU, Roberts TPL, Nelson CA, Marsh ED. Evoked potentials and EEG analysis in Rett syndrome and related developmental encephalopathies: towards a biomarker for translational research. Front Integr Neurosci. 2020;14:30.","journal-title":"Front Integr Neurosci"},{"key":"8678_CR72","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s11689-019-9275-z","volume":"11","author":"KJ Roche","year":"2019","unstructured":"Roche KJ, LeBlanc JJ, Levin AR, O\u2019Leary HM, Baczewski LM, Nelson CA. Electroencephalographic spectral power as a marker of cortical function and disease severity in girls with Rett syndrome. J Neurodev Disord. 2019;11:15.","journal-title":"J Neurodev Disord"},{"key":"8678_CR73","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1002\/ana.24513","volume":"78","author":"JJ LeBlanc","year":"2015","unstructured":"LeBlanc JJ, DeGregorio G, Centofante E, Vogel-Farley VK, Barnes K, Kaufmann WE, Fagiolini M, Nelson CA. Visual evoked potentials detect cortical processing deficits in Rett syndrome. Ann Neurol. 2015;78:775\u201386.","journal-title":"Ann Neurol"},{"key":"8678_CR74","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1097\/DBP.0000000000000815","volume":"41","author":"P Jacoby","year":"2020","unstructured":"Jacoby P, Epstein A, Kim R, Murphy N, leonard H, williams k, reddihough d, whitehouse a, downs j. reliability of the quality of life inventory-disability (QI-Disability) measure in children with intellectual disability. J Dev Behav Pediatr. 2020;41:534\u20139.","journal-title":"J Dev Behav Pediatr"},{"key":"8678_CR75","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/cch.12691","volume":"45","author":"A Epstein","year":"2019","unstructured":"Epstein A, Williams K, Reddihough D, Murphy N, Leonard H, Whitehouse A, Jacoby P, Downs J. Content validation of the Quality of Life Inventory-Disability. Child Care Health Dev. 2019;45:654\u20139.","journal-title":"Child Care Health Dev"},{"key":"8678_CR76","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1136\/jmedgenet-2020-107120","volume":"58","author":"J Mendoza","year":"2021","unstructured":"Mendoza J, Downs J, Wong K, Leonard H. Determinants of quality of life in Rett syndrome: new findings on associations with genotype. J Med Genet. 2021;58:637\u201344.","journal-title":"J Med Genet"},{"key":"8678_CR77","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/cch.12873","volume":"47","author":"D Reddihough","year":"2021","unstructured":"Reddihough D, Leonard H, Jacoby P, Kim R, Epstein A, Murphy N, Reid S, Whitehouse A, Williams K, Downs J. Comorbidities and quality of life in children with intellectual disability. Child Care Health Dev. 2021;47:654\u201366.","journal-title":"Child Care Health Dev"},{"key":"8678_CR78","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/dmcn.14657","volume":"63","author":"K Williams","year":"2021","unstructured":"Williams K, Jacoby P, Whitehouse A, Kim R, Epstein A, Murphy N, Reid S, Leonard H, Reddihough D, Downs J. Functioning, participation and quality of life in children with intellectual disability: An observational study. Dev Med Child Neurol. 2021;63:89\u201396.","journal-title":"Dev Med Child Neurol"},{"key":"8678_CR79","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1212\/WNL.0b013e3182377dd2","volume":"77","author":"JB Lane","year":"2011","unstructured":"Lane JB, Lee HS, Smith LW, Cheng P, Percy AK, Glaze DG, Neul JL, Motil KJ, Barrish JO, Skinner SA, Annese F, McNair L, Graham J, Khwaja O, Barnes K, Krischer JP. Clinical severity and quality of life in children and adolescents with Rett syndrome. Neurology. 2011;77:1812\u20138.","journal-title":"Neurology"},{"key":"8678_CR80","unstructured":"Food and Drug Administration. Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-forPurpose Clinical Outcome Assessments Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders (Draft Guidance).\u00a0US Department of Health and Human Services; 2022. https:\/\/www.fda.gov\/media\/159500\/download. Accessed 13 Dec 2024."},{"key":"8678_CR81","doi-asserted-by":"crossref","unstructured":"Sigafoos J, Roche L, O'Reilly MF, Lancioni GE, Marschik PB. Updated systematic-narrative review on communication intervention in Rett Syndrome: 2010\u20132022. Augment Altern Commun. 2023;39:241\u201355.","DOI":"10.1080\/07434618.2023.2215864"},{"key":"8678_CR82","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s11136-023-03543-6","volume":"33","author":"J Downs","year":"2024","unstructured":"Downs J, Ludwig NN, Wojnaroski M, Keeley J, Schust Myers L, Chapman CAT, Hecker J, Conecker G, Berg AT. What does better look like in individuals with severe neurodevelopmental impairments? A qualitative descriptive study on SCN2A-related developmental and epileptic encephalopathy. Qual Life Res. 2024;33:519\u201328.","journal-title":"Qual Life Res"},{"key":"8678_CR83","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s41687-019-0100-y","volume":"3","author":"H Staunton","year":"2019","unstructured":"Staunton H, Willgoss T, Nelsen L, Burbridge C, Sully K, Rofail D, Arbuckle R. An overview of using qualitative techniques to explore and define estimates of clinically important change on clinical outcome assessments. J Patient Rep Outcomes. 2019;3:16.","journal-title":"J Patient Rep Outcomes"},{"key":"8678_CR84","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.4155\/cli.11.113","volume":"1","author":"K Bushby","year":"2011","unstructured":"Bushby K, Connor E. Clinical outcome measures for trials in Duchenne muscular dystrophy: report from International Working Group meetings. Clin Investig (Lond). 2011;1:1217\u201335.","journal-title":"Clin Investig (Lond)"},{"key":"8678_CR85","doi-asserted-by":"publisher","first-page":"e0266351","DOI":"10.1371\/journal.pone.0266351","volume":"18","author":"PB Suresha","year":"2023","unstructured":"Suresha PB, O\u2019Leary H, Tarquinio DC, von Hehn J, Clifford GD. Rett syndrome severity estimation with the BioStamp nPoint using interactions between heart rate variability and body movement. PLoS ONE. 2023;18:e0266351.","journal-title":"PLoS ONE"},{"key":"8678_CR86","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/0197-2456(89)90005-6","volume":"10","author":"R Jaeschke","year":"1989","unstructured":"Jaeschke R, Singer J, Guyatt GH. Measurement of health status: Ascertaining the minimal clinically important difference. Contemp Clin Trials. 1989;10:407\u201315.","journal-title":"Contemp Clin Trials"},{"key":"8678_CR87","doi-asserted-by":"crossref","unstructured":"Bruni O, Ottaviano S, Guidetti V, Romoli M, Innocenzi M, Cortesi F, Giannotti F. The Sleep Disturbance Scale for Children (SDSC). Construction and validation of an instrument to evaluate sleep disturbances in childhood and adolescence. J Sleep Res 1996;5:251\u201361.","DOI":"10.1111\/j.1365-2869.1996.00251.x"},{"key":"8678_CR88","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1093\/sleep\/23.8.1d","volume":"23","author":"JA Owens","year":"2000","unstructured":"Owens JA, Spirito A, McGuinn M. The Children\u2019s Sleep Habits Questionnaire (CSHQ): psychometric properties of a survey instrument for school-aged children. Sleep. 2000;23:1043\u201351.","journal-title":"Sleep"},{"key":"8678_CR89","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s40675-023-00272-7","volume":"10","author":"SJ Jaiswal","year":"2024","unstructured":"Jaiswal SJ, Pawelek JB, Warshawsky S, Quer G, Trieu M, Pandit JA, Owens RL. Using new technologies and wearables for characterizing sleep in population-based Studies. Current Sleep Med Repo. 2024;10:82\u201392.","journal-title":"Current Sleep Med Repo"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-024-08678-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-024-08678-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-024-08678-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T15:02:13Z","timestamp":1734793333000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-024-08678-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,21]]},"references-count":89,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["8678"],"URL":"https:\/\/doi.org\/10.1186\/s13063-024-08678-6","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,21]]},"assertion":[{"value":"12 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Workshop involving literature review, ethics approval not necessary for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not necessary for this study. Workshop participants are the authors for this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JD: Consultancy for Marinus, Ultragenyx, Acadia, Avexis, Orion, Neurogene, Taysha and Takeda; Clinical Trials with Anavex and Newron. All consultancies are unrelated to this work and all remuneration has been made to her department.DCP: None.WEK: Past Chief Scientific Officer of Anavex Life Sciences Corp. He received funding from the National Institutes of Health (NIH) and the Centers for Disease Control and Prevention (CDC), and he has been a consultant for Anavex, Acadia, EryDel\/Quince, Neuren, Newron, GW Pharmaceuticals, Marinus, Biohaven, Zynerba, Ovid Therapeutics, Stalicla, Unravel Biosciences and Tetra Therapeutics. He has done clinical trials with Ipsen and Neuren.JPH: Employee at AMO Pharma, based in Wornesh, United Kingdom.MR: None.GT: None.EM: The PI for Stoke therapeutics, Zogenix Pharmaceuticals, Acadia Pharmaceuticals, Marinus Pharmaceuticals, Takeda Pharmaceuticals, Epygenix Pharmaceuticals. He has received research support from NIH, Penn Orphan Disease center, International Rett syndrome foundation, International CDKL5 Research Foundation, Curaleaf Inc., is a consultant for Acadia Pharmaceuticals, and has prepared an educational programme for Medscape.HL: Consultancy for Marinus, Acadia, Avexis and Orion; Clinical Trials with Anavex and Newron; All remuneration has been made to her department.KM: None.ACD: Work completed while an employee and equity holder of Shape Therapeutics, Inc. Current employee and equity holder of Ensoma, which had no oversight or funding of this work.NG: None.AA: Research funding from Acadia Pharmaceuticals, Zogenix Inc. Consulting for Sanofi, Acadia.BB: Currently research funding from the NIH (NICHD) and Acadia Pharmaceuticals.SP: Dr. Peters has received research funding from the MECP2 Duplication Foundation, the ActiGraph Corporation, and the National Institutes of Health. She is a consultant for Ionis Pharmaceuticals and Acadia Pharmaceuticals.CB: Consultant for Acadia Pharmaceuticals.FS: None.AJ: None.JY: Employee of Acadia Pharmaceuticals.BS: Received research funding from the International Foundation for CDKL5 Research, Loulou Foundation, the National Institutes of Health, International Rett Syndrome Foundation, the Rett Syndrome Research Trust, and the Grace Science Foundation; consultancy for the IONIS pharmaceuticals, Neurogene, and Taysha; clinical trials with Acadia Pharmaceuticals Inc., Marinus Pharmaceuticals, Neurogene, and the Rett Syndrome Research Trust. All remuneration has been paid to Baylor College of Medicine.PS: Lead of the CIPP Rett Centre, UK, which is partially funded by Reverse Rett, UK. P.S. was a previous Principal Investigator (PI) in the Sarizotan (Protocol Number Sarizotan\/001\/II\/2015; ClinicalTrials.gov Identifier: NCT02790034) and the Anavex Life Sciences Corp. (Protocol Number: ANAVEX2-73-RS-002) clinical trial on Rett Syndrome (RTT). P.S. is currently the PI in the Anavex Life Sciences Corp. (Protocol Number: ANAVEX2-73-RS-003) clinical trial. P.S. is the co-inventor of the HealthTrackerTM and is the Chief Executive Officer and shareholder in HealthTrackerTM.JLN: Received research funding from the National Institutes of Health, the International Rett Syndrome Foundation, and Rett Syndrome Research Trust; served as investigator for clinical trials conducted by Acadia Pharmaceuticals, GW Pharmaceuticals, Neuren Pharmaceuticals, and Newron; received personal consultancy for Acadia Pharmaceuticals Inc, Analysis Group, Anavex, AveXis, GW Pharmaceuticals, Hoffmann-La Roche, Ionis Pharmaceuticals, Myrtelle, Neurogene, Newron Pharmaceuticals, Signant Health, and Taysha Gene Therapies, and the preparation of CME activities for the France Foundation, MedEdicus, Medscape, PeerView Institute, Medscape, TotalCME; served on the scientific advisory board of Alcyone Lifesciences; was a scientific co-founder of LizarBio Therapeutics; and a member of a data safety monitoring board for clinical trials conducted by Ovid Therapeutics and Ultragenix.TAB: Received research funding from GRIN2B Foundation, the International Foundation for CDKL5 Research, Loulou Foundation, the National Institutes of Health, and Simons Foundation; consultancy for Alcyone, AveXis, GRIN Therapeutics, GW Pharmaceuticals, the International Rett Syndrome Foundation, Marinus Pharmaceuticals, Neurogene, Ovid Therapeutics, and Takeda Pharmaceutical Company Limited; clinical trials with Acadia Pharmaceuticals Inc., GW Pharmaceuticals, Marinus Pharmaceuticals, Ovid Therapeutics, and Rett Syndrome Research Trust; all remuneration has been made to his department.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"845"}}